MedTrace Logo

TAVR for Aortic Valve Disease

NCT05439863 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2024-11-15

No results posted yet for this study

Summary

Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.

Conditions

  • Aortic Valve Disease

Interventions

DEVICE

transcatheter heart valve

patients with severe aortic valve disease underwent transcatheter heart valve

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2032-12-30
Completion
2037-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05439863 on ClinicalTrials.gov